{
    "clinical_study": {
        "@rank": "129352", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective, national, multicenter, observational study will evaluate in routine\n      clinical practice the efficacy and safety of re-treatment with Pegasys (peginterferon\n      alfa-2a) plus ribavirin or regimens containing direct-acting antivirals in patients with\n      chronic hepatitis C who failed previous treatment. Patients will be followed for the\n      duration of their treatment (24, 48 or 72 weeks) and for 24 weeks of follow-up."
        }, 
        "brief_title": "An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Patients with chronic hepatitis C who have been previously treated with pegylated\n             interferon, standard interferon, ribavirin\n\n          -  No contra-indications to pegylated interferon and ribavirin therapy or to the\n             treatment regimen containing DAAs as detailed in the local label\n\n          -  Treatment in line with summary of Product Characteristics/local labeling for\n             Pegasys/ribavirin and DAAs, in particular:\n\n               -  Positive serum HCV RNA\n\n               -  Fertile males and females receiving ribavirin must use two forms of\n                  contraception during treatment with Pegasys/ribavirin and until 6 months\n                  post-treatment\n\n               -  No co-infection with hepatitis B or HIV\n\n        Exclusion Criteria:\n\n          -  History or other evidence of a medical condition associated with chronic liver\n             disease other than chronic hepatitis C\n\n          -  History of neurological disease\n\n          -  History of severe psychiatric disease\n\n          -  Decompensated diabetes\n\n          -  History of immunologically mediated disease\n\n          -  History of severe cardiac disease\n\n          -  History or evidence of severe chronic pulmonary disease\n\n          -  Inadequate hematologic function\n\n          -  Pregnant or breastfeeding women\n\n          -  Male partners of pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Treatment-experienced patients with chronic hepatitis C receiving re-treatment with\n        Pegasys plus ribavirin or regimens containing direct-acting antivirals (DAAs)"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798576", 
            "org_study_id": "ML28498"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brasov", 
                    "country": "Romania", 
                    "zip": "500326"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Romania"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28498 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Romania: National Medicines Agency"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sustained virological response (SVR) rate, defined as percentage of patients with HCV RNA <50 IU/mL at 24 weeks post completion of treatment (overall and stratified by prior treatment outcome: non-response and relapse)", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798576"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with rapid virological response (RVR), defined as HCV RNA <50 IU/mL at Week 4 (overall and stratified by prior treatment outcome: non-response and relapse)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Percentage of patients with early virological response (EVR), defined as HCV RNA <50 IU/mL or an at least 2-log drop from baseline in HCV RNA at Week 12, but with no RVR (overall and stratified by prior treatment outcome: non-response and relapse)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Percentage of patients with non-response/relapse/virological breakthrough/virological rebound", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Duration of treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Time to safety-related dose reduction/treatment discontinuation of any of the treatment compounds", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}